IPP Bureau
Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22
By IPP Bureau - August 08, 2021
Board approves fundraise of Rs 1500 crore
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
By IPP Bureau - August 08, 2021
The company expects revenue growth of 10-15 per cent in the US
Abbott India net profit rises to 8.5 per cent in Q1FY22
By IPP Bureau - August 08, 2021
PAT rises to Rs 195.76 crore
TAKE divests stake in Navitas Life Sciences to HIG
By IPP Bureau - August 08, 2021
The transaction is expected to close in the Q4FY22
Cipla posts net profit at Rs 715 crores
By IPP Bureau - August 08, 2021
India business contributes to a stellar performance
Divi's Labs posts a 13 per cent rise in PAT at Rs 557.11 crore
By IPP Bureau - August 08, 2021
Forex gains stood at Rs 20 crore for the quarter
Alkem launches Ibuprofen and Famotidine tablets in US
By IPP Bureau - August 07, 2021
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Sanofi to acquire Translate Bio
By IPP Bureau - August 07, 2021
Advances deployment of mRNA technology across vaccines and therapeutics development
Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr
By IPP Bureau - August 07, 2021
This robust growth has come despite the raging pandemic for most part of the quarter
SPI Pharma partners Azelis Americas
By IPP Bureau - August 07, 2021
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Stelis Biopharma appoints Mark W. Womack as CEO
By IPP Bureau - August 07, 2021
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Strides to acquire US manufacturing facility of Endo for $24 mn
By IPP Bureau - August 06, 2021
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Mark W. Womack is the new CEO of Stelis Biopharma
By IPP Bureau - August 06, 2021
He will be stationed at the company HQ in Bengaluru, India
Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
By IPP Bureau - August 06, 2021
CDSCO to fast-track trials and approval for COVID19 vaccine
India’s gets its first bio-bank for heart failure research
By IPP Bureau - August 06, 2021
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
